Blue Sail Medical Co., Ltd. Announcement on the Completion of the Implementation of the Share Increase Plan for the Directors and the Actual Controller

2026-04-08 03:03:19

Stock code: 002382 Stock abbreviation: Bluerun Medical Announcement No.: 2026-028

Bond code: 128108 Bond abbreviation: Bluerun Convertible Bonds

Bluerun Medical Co., Ltd.

Announcement on the completion of the implementation of the share purchase plan by the directors and the actual controller

Directors and the actual controller Li Zhenping shall ensure that the information provided to our company is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.

Our company and all members of the board of directors guarantee that the content of this announcement is consistent with the information provided by the information-disclosure obligor.

Special Notice:

Basic situation of the share purchase plan: Bluerun Medical Co., Ltd. (hereinafter referred to as the “Company”) disclosed on April 2, 2026 the Announcement on the Share Purchase Plan by the Director and the Actual Controller (Announcement No.: 2026-027). Within 1 week from the date of disclosure of this share purchase plan announcement (April 2, 2026–April 8, 2026), Company director and actual controller Li Zhenping intends to purchase shares of the Company. The total amount of this planned share purchase will not be less than RMB 20 million (inclusive).
Completion status of the share purchase plan: As of the date of disclosure of this announcement, Li Zhenping’s share purchase plan has been implemented and completed. On April 2, 2026, Li Zhenping purchased a total of 2,472,299 shares, representing 0.25% of the Company’s total share capital, with a purchase amount of RMB 20.4996 million, which is not less than the lower limit of the promised share purchase amount.

The Company has recently received the Notice Letter on the Results of Implementation of the Share Purchase Plan issued by director and actual controller Li Zhenping. The relevant details are hereby announced as follows:

I. Basic information on the share purchase entity

Basic information on the share purchase entity: Company director and actual controller Li Zhenping
Shareholding of the share purchase entity: Before the implementation of this share purchase plan, Li Zhenping directly held 5,552,618 shares of the Company, accounting for 0.55% of the Company’s current total share capital, and held 234,781,123 shares of the Company through Zibo Bluerun Investment Co., Ltd., accounting for 23.31% of the Company’s current total share capital.
Within the 12 months prior to the disclosure of this announcement, Li Zhenping has not disclosed any share purchase plan. Within the 6 months prior to the disclosure of this announcement, there has been no instance of reducing its holdings of the Company’s shares.

II. Main contents of the share purchase plan

Purpose of the share purchase: Based on firm confidence in the Company’s intrinsic value and its future sustained, stable and healthy development, as well as to protect shareholders’ interests and enhance investors’ confidence, Li Zhenping intends to increase its shareholding in the Company.
Number or amount of shares to be purchased: The amount for this planned share purchase shall be not less than RMB 20 million (inclusive).
Purchase price: This share purchase plan does not set a price range. It will be implemented opportunistically in accordance with fluctuations in the Company’s stock price and the overall trends of the capital market.
Implementation period of the share purchase plan: Taking into account factors such as market volatility and funding arrangements, Li Zhenping plans to increase its shareholding in the Company opportunistically within 1 week from the date of disclosure of this share purchase plan announcement (April 2, 2026–April 8, 2026) (excluding the period in which share purchases are not allowed in accordance with laws and regulations, rules of the Shenzhen Stock Exchange, and other relevant provisions). If the Company’s stock is suspended during the implementation period of the share purchase plan, the share purchase plan will be carried out in a delayed manner after the stock resumes trading and will be disclosed in a timely manner.
Share purchase method: It is planned to increase shareholding through the centralized bidding trading method on the Shenzhen Stock Exchange.
Source of funds for the share purchase: It is planned to use self-owned funds or funds raised for the share purchase.
This share purchase plan is not based on the specific identity of the share purchase entity. If the relevant identity is lost, the share purchase plan will continue to be implemented.
Except for the lock-up period specified by the relevant rules, there are no other lock-up arrangements in this share purchase plan.
Undertaking of the share purchase entity: During the implementation period of this share purchase plan and within the statutory period, it will not reduce the Company shares held. It will strictly comply with the provisions of relevant laws and regulations. Within the implementation period, it will complete the share purchase plan and will not engage in insider trading, trading of shares during sensitive periods, short-term trading, or other such conduct.

III. Results of the implementation of the share purchase plan

On April 2, 2026, Li Zhenping purchased 2,472,299 shares of the Company in the secondary market through the trading system of the Shenzhen Stock Exchange by means of centralized bidding, accounting for 0.25% of the Company’s total share capital. The purchase amount was RMB 20.4996 million. The transaction amount of the shares purchased under this share purchase plan meets the pre-determined share purchase plan, and the share purchase plan has been completed.

Li Zhenping’s shareholding situation before and after the share purchase is as follows:

■

IV. Other relevant explanations

This share purchase complies with relevant provisions of the Company Law of the People’s Republic of China, the Measures for the Administration of Takeovers of Listed Companies, and other laws and regulations, departmental rules, and the operating rules of the Shenzhen Stock Exchange, etc.
The implementation of this share purchase plan will not affect the Company’s listing status, will not result in the Company’s share distribution failing to meet the listing conditions, and will not result in changes to the Company’s controlling shareholder and actual controller.
Undertaking by the purchaser: After the completion of this share purchase, it will not reduce the Company shares held during the statutory lock-up period in accordance with relevant laws and regulations and relevant provisions of the Shenzhen Stock Exchange. When transferring the Company shares in the future, it will strictly comply with the provisions of laws, regulations, and the Company’s relevant systems.
The Company will continue to monitor the changes in the shares of director and actual controller Li Zhenping, and will fulfill its information disclosure obligations in a timely manner in accordance with relevant provisions. Investors are kindly requested to pay attention to investment risks.

V. Documents for reference

The Notice Letter on the Results of Implementation of the Share Purchase Plan.

This announcement is hereby issued.

Bluerun Medical Co., Ltd.

Board of Directors

April 4, 2026

Stock code: 002382 Stock abbreviation: Bluerun Medical Announcement No.: 2026-029

Bond code: 128108 Bond abbreviation: Bluerun Convertible Bonds

Bluerun Medical Co., Ltd.

Announcement on the preliminary notification of the controlling shareholder and its persons acting in concert reaching a 1% integer multiple change in shareholding ratio

The Company’s controlling shareholder Zibo Bluerun Investment Co., Ltd., and director and actual controller Li Zhenping, guarantee that the information provided to our company is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.

Our company and all members of the board of directors guarantee that the content of this announcement is consistent with the information provided by the information-disclosure obligor.

Recently, Bluerun Medical Co., Ltd. (hereinafter referred to as the “Company”) received the Notice Letter on the Results of Implementation of the Share Purchase Plan issued by director and actual controller Li Zhenping. On April 2, 2026, Li Zhenping purchased 2,472,299 shares of the Company by means of centralized bidding. The shareholding change of the controlling shareholder Zibo Bluerun Investment Co., Ltd. (hereinafter referred to as “Bluerun Investment”) and its persons acting in concert, director and actual controller Li Zhenping, reached a 1% integer multiple.

The relevant information is hereby announced as follows:

■

This announcement is hereby issued.

Bluerun Medical Co., Ltd.

Board of Directors

April 4, 2026

Endless information, precise interpretation—everything is on the Sina Finance app

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.